肺アスペルギロシスが自発性肺胸炎の手術治療中に診断された: 症例報告
Masanori Okada1, Riki Okita1, Hidetoshi Inokawa1
1Division of Thoracic Surgery, National Hospital Organization Yamaguchi Ube Medical Center, Ube, Yamaguchi, Japan.
AME case reports
|February 12, 2026
まとめ
このケースは,自発的な肺胸外科手術後の慢性肺アスペルギロシス (CPA) 診断を強調しています. 肺胞や肺胸炎の患者にCPAを早期に検討することは,適切な治療に不可欠です.
科学分野:
- 肺内科 肺内科 肺内科
- 感染症 感染症は感染症です.
- 医療事例報告 症例報告
背景:
- 慢性肺アスペルギロシス (CPA) は無症状であり,呼吸器系症状または胸部画像の偶然の発見によって診断されることが多い.
- 自発性肺胸症は,さまざまな肺疾患の既知の合併症ですが,CPAとの関連はまれです.
研究 の 目的:
- 慢性肺アスペルギロシス (CPA) のまれな症例を報告するために,自発性肺胸外科手術の後に手術後に診断されました.
- Pneumothoraxと既にある肺異常を呈する患者においてCPAを考慮する重要性を強調する.
主な方法:
- 継続的な空気漏れとエンピーエマを伴う自発的な肺胸炎に対する外科介入.
- 軟管を阻害する死体質の内科的識別と切除.
- 切断された組織の組織病理学的検査と真菌培養.
- 経口用ヴォリコナゾールによる術後の治療.
主要な成果:
- 手術調査により,フィスチュラを阻害する死体質が明らかになり,局所肺アスペルギロシスの診断に至った.
- アスペルギルス・フミガトゥスは,切断された死体物質から特定されました.
- 86歳の患者で,プレドニゾロンを服用していた患者は,外科的除菌と抗真菌治療の後に無事回復し,2年間の追跡調査で再発しなかった.
結論:
- CPAは,肺胸炎の患者,特に以前の結核から発症したシスティック肺の変化のある患者では考慮する必要があります.
- 迅速な外科的および抗真菌管理は,高齢で免疫力が低下した患者でも成功する結果をもたらすことができます.
- このケースは,複雑な肺疾患における徹底した手術内評価と微生物学的評価の重要性を強調しています.
関連する概念動画
Pneumothorax-I
1.4K
A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
1.4K
Pneumothorax-II
1.1K
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
1.1K
Spontaneity
30.2K
A spontaneous process is one that occurs naturally under certain conditions. A nonspontaneous process, on the other hand, will not take place unless it is “driven” by the continual input of energy from an external source. Processes have a natural tendency to occur in one direction under a given set of conditions. Water will naturally flow downhill (spontaneous process), but uphill flow (nonspontaneous process) requires outside intervention such as the use of a pump. Iron exposed to...
30.2K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
625
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
625
Diagnosing Acidosis and Alkalosis
1.3K
Diagnosing acid-base imbalances involves systematically analyzing arterial blood samples, focusing on three key measurements: pH, bicarbonate (HCO3−) concentration, and carbon dioxide partial pressure (PCO2). This analysis follows a four-step process that helps identify the imbalance's underlying cause and nature.
First, the pH level is assessed to determine whether the blood pH is normal (7.35–7.45), low (acidosis), or high (alkalosis).
Next, the PCO2 and...
First, the pH level is assessed to determine whether the blood pH is normal (7.35–7.45), low (acidosis), or high (alkalosis).
Next, the PCO2 and...
1.3K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
484
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
484


